RxDoctor Payments Data

Jacqueline Fincher, MD

Internal Medicine · Thomson, GANPI 1710985403

Payments from drug & device makers

$868in general payments, 2019–2025

Across 25 payments — averaging $34.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$232
  • Novo Nordisk$214
  • AstraZeneca$124
  • Abbott$93
  • Pfizer$44
  • AbbVie$40
  • plus $121 from 7 others

What the payments were for

  • Food & beverage$83496%
  • Education$334%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$868 in reported general payments places this provider in the 65th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$154,925
Medicare patients
138
Services billed
6,872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban199$185,769
FarxigaDapagliflozin Propanediol180$166,395
OzempicSemaglutide139$157,362
JardianceEmpagliflozin170$138,668
TrulicityDulaglutide46$65,875
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$56,672
JanuviaSitagliptin Phosphate42$42,266
RybelsusSemaglutide20$34,483
XareltoRivaroxaban36$33,146
ArexvyRsvpref3 Antigen/As01e/Pf102$31,122
LinzessLinaclotide33$29,364
MounjaroTirzepatide24$25,750
MyrbetriqMirabegron42$25,523
Breo ElliptaFluticasone/Vilanterol32$18,430
TradjentaLinagliptin12$16,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$214$191,845159 claims
PfizerEliquis$44$185,769199 claims
AstraZenecaFarxiga, Symbicort$124$173,906211 claims
Boehringer IngelheimJardiance, Tradjenta$11$154,683182 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Shingrix$30$114,135230 claims
MerckJanuvia, Janumet$17$54,89857 claims
Johnson & JohnsonXarelto$13$33,14636 claims
AbbVieLinzess, Synthroid$40$32,32065 claims
NovartisEntresto$34$7,83811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Thomson

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →